LexaGene is a molecular diagnostics company developing the MiQLab™, a rapid, fully automated pathogen detection system for use at the point-of-need in human clinical diagnostics and veterinary diagnostics, as well as food safety testing, and open-access markets that need critical answers in less time.
LexaGene’s patented microfluidic system was invented by company CEO and Founder, Dr. Jack Regan, who was a lead scientist in developing a predecessor instrument designed for bio-warfare surveillance that was adopted by the Department of Homeland Security for the BioWatch Program and a second R&D instrument that was designed for detecting respiratory pathogens from nasal swab samples. The development of these instruments was supported by $20M in government funding.
LexaGene’s experienced leadership team is driving company growth with a focus on innovation, pursuing unique market opportunities, and providing shareholder value.
11th Floor 1050
West Pender St.
V6E 3S7 Canada
Royal Centre, 1055 West Georgia Street
Suite 1500, PO Box 11117
Canada V6E 4N7
For more information, please visit the Computershare website: